←Back to all issuesIssue No. 03Culture5 min readMarch 9, 2026
Who is talking about peptides, and what are they actually saying?
A careful look at the public figures driving the peptide conversation — what they have said on the record, and how to think about it.
Who is talking about peptides, and what are they actually saying?
A careful look at the public figures driving the peptide conversation — what they have said on the record, and how to think about it.
|
Who is talking about peptides, and what are they actually saying?
|
|
A careful look at the public figures driving the peptide conversation — what they've said on the record, and how to think about it.
|
|
|
Dear Pru Community,
|
|
Peptide therapy went mainstream because a handful of high-profile people talked about it — openly, repeatedly, and in front of very large audiences. That's just the truth of how it happened.
|
|
That's worth taking seriously in both directions. Public enthusiasm about a medical treatment isn't proof it works — but it's also not nothing, especially when some of the people speaking have professional reputations and scientific credentials on the line. The question worth asking isn't "is this person famous?" It's "what did they actually say, and what's the basis for it?"
|
|
This issue profiles four of the key figures driving the peptide conversation. For each, we've documented only what they've said on the record — in interviews, podcasts, or official public statements — and noted whether they're speaking as a user, a scientist, or a policymaker.
|
|
|
JOE ROGAN
|
|
Podcast host, The Joe Rogan Experience. Approximately 14 million listeners per episode.
|
|
Rogan has probably done more than anyone to put peptides in front of a general audience — almost entirely through personal experience. He described using BPC-157 for elbow tendinitis that he couldn't otherwise fix, saying it cleared up within two weeks. He's discussed BPC-157, TB-500, Ipamorelin, CJC-1295, and Thymosin Alpha-1 across multiple episodes. In a January 2026 episode with Matt Damon and Ben Affleck, he described the BPC-157 and TB-500 combination as allowing the body to "heal like you're a fucking six-year-old" — a phrase that subsequently made the rounds online. Worth noting: Rogan has mentioned working with clinical providers rather than unregulated vendors, which reflects genuine care about sourcing. He's not just buying things off the internet.
|
|
|
|
Personal experience is actually how medicine often first identifies compounds worth studying. Rogan's reach has introduced peptides to millions of people who might never have encountered them through clinical channels — and for many, that introduction became the first step toward a real conversation with their provider.
|
|
|
ANDREW HUBERMAN, PH.D.
|
|
Professor of Neurobiology and Ophthalmology, Stanford University School of Medicine. Host, Huberman Lab podcast.
|
|
Huberman's April 2024 episode on peptide therapeutics is probably the most scientifically grounded public treatment of the topic that exists from a credentialed researcher. He covered four specific areas of therapeutic potential: faster wound healing and tissue repair, increased deep sleep, support of growth hormone and IGF-1 pathways, and circadian rhythm recalibration. On BPC-157, he laid out a precise mechanism — the peptide promotes angiogenesis, fibroblast migration, and cellular turnover at injury sites, accelerating healing across tendons, ligaments, and muscle simultaneously. He called peptides an "emerging frontier for regenerative medicine." On growth hormone secretagogues like Sermorelin, Ipamorelin, and CJC-1295, he made a point that's worth highlighting: these compounds stimulate the body's own pituitary to produce growth hormone naturally, rather than introducing it exogenously. That distinction matters for both physiological coherence and long-term safety. Huberman has himself used BPC-157 for chronic lower back pain from a herniated disc and Sermorelin for its effects on GH release and sleep.
|
|
|
|
What makes Huberman's contribution meaningful is that he brings a researcher's framework to the conversation — not just "this worked for me," but here's the mechanism, here's why the biology supports it. His discussion of how these compounds work elevates the conversation from testimonial to something much closer to scientific literacy.
|
|
|
ROBERT F. KENNEDY JR.
|
|
U.S. Secretary of Health and Human Services.
|
|
Kennedy is the only person on this list whose views on peptides have had direct regulatory consequences. On February 27, 2026, during Episode #2461 of The Joe Rogan Experience, he called himself a "big fan of peptides," said he uses them personally, and announced that the FDA would be moving approximately 14 of the 19 restricted peptides back to Category 1 status within weeks. He described the 2023 restrictions as having been made "illegally" and as having "created the gray market" — and framed his goal as giving Americans access to these compounds "from ethical suppliers." His advocacy predates his HHS appointment. In a May 2025 appearance on Gary Brecka's podcast, he promised to "end the war at FDA" on peptides, stem cells, and other therapies that hadn't found their way into mainstream medicine.
|
|
|
|
What makes Kennedy's position notable is that it's consequential. He's a sitting U.S. public health official using his platform and authority to argue that supervised access to these compounds through regulated channels is a legitimate health policy priority — and that the alternative (a thriving gray market with zero quality controls) is the actual safety problem. That argument has a real public health logic behind it, and it's now shaping federal policy.
|
|
|
BRYAN JOHNSON
|
|
Tech entrepreneur. Founder, Project Blueprint and OS Fund. Self-described "most measured human."
|
|
Johnson occupies a category of his own here. He's not a scientist or a policymaker — he's a systematic self-experimenter who has made the radical transparency of his own biology into a public project. His Blueprint protocol, developed with a team of over 30 physicians and specialists, involves continuous biomarker tracking across hundreds of variables — biological age, organ function, inflammatory markers, telomere length, hormonal balance — with the explicit goal of slowing and reversing biological aging. Peptides run throughout the protocol at multiple levels. He takes 12.5 grams of collagen peptides daily as part of his morning Longevity Mix for structural support of joints, skin, and connective tissue. He's used injectable BPC-157 and TB-500 cyclically for injury recovery, and Cerebrolysin — a peptide-based nootropic with a long clinical history in Eastern Europe — for cognitive performance. His topical serum stack incorporates eight biomimetic peptides including Thymosin Beta-4, copper tripeptide-1, and growth factor peptides for skin and scalp health. What distinguishes Johnson is the framework: he describes his protocol as an "N-of-1 experiment" — a single-subject study where he is simultaneously the researcher and the subject — and publishes his methods, results, and biomarker data publicly.
|
|
|
|
Johnson's significance to this conversation is as much methodological as personal. In a space where most advocacy is purely anecdotal, his insistence on measuring outcomes — and publishing them — is a more rigorous approach than most public figures bother with. He's not running a clinical trial. But he's asking the right questions, in the right direction, with more data than almost anyone else doing this publicly.
|
|
|
How to engage with this conversation
|
|
Peptide therapy has moved from a niche clinical conversation to a mainstream cultural one in roughly two years, driven primarily by podcast audiences rather than peer-reviewed journals. That creates real opportunity — it generates demand for research that might not otherwise be funded, and it's contributed to regulatory reform that appears to be moving in a genuinely constructive direction.
|
|
At Pru, our protocols don't start with podcasts. They start with your labs, your health history, and a conversation with a licensed provider who understands the evidence landscape fully — including where it's strong, where it's still emerging, and where it's genuinely uncertain. The public conversation that Huberman, Rogan, Kennedy, and Johnson are driving is meaningful. Turning that interest into a protocol that's actually safe, appropriate, and useful for your biology is exactly what Pru is here for.
|
|
|
WORTH LISTENING
|
|
Huberman, A. (April 1, 2024). Benefits and Risks of Peptide Therapeutics for Physical and Mental Health. Huberman Lab Podcast. The most thorough public scientific treatment of therapeutic peptides from a credentialed researcher — a genuinely useful starting point before any conversation with your provider.
|
|
|
Want more like this?
Subscribe to get new issues delivered to your inbox. No spam, unsubscribe anytime.